Epi-immunotherapy appears promising for hepatocellular carcinoma (HCC) treatment, but the therapeutic efficacy is limited by the immunosuppressive tumor microenvironment. Here this group reports co-delivering siRNA targeting YTHDF1 and the histone deacetylase IIa inhibitor TMP195, which enables the epigenetic reprogramming of HCC tumor cells and macrophages repolarization to enhance the immunotherapeutic response against HCC.
